These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38647051)

  • 41. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
    Chou S; Marousek GI
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Limaye AP
    Clin Infect Dis; 2021 Nov; 73(9):e2739-e2745. PubMed ID: 32712663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
    Frange P; Leruez-Ville M
    Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
    Bright PD; Gompels M; Donati M; Johnston S
    J Clin Virol; 2017 Feb; 87():12-16. PubMed ID: 27987421
    [No Abstract]   [Full Text] [Related]  

  • 46. New Treatment Options for Refractory/Resistant CMV Infection.
    Walti CS; Khanna N; Avery RK; Helanterä I
    Transpl Int; 2023; 36():11785. PubMed ID: 37901297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS.
    Tsui JC; Huang V; Kolomeyer AM; Miller CG; Mishkin A; Maguire AM
    Retin Cases Brief Rep; 2024 Mar; 18(2):164-167. PubMed ID: 36730596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful Use of Maribavir for Drug-resistant Cytomegalovirus Colitis in a Heart Transplant Recipient.
    Zegrí Reiriz I; Gómez-Bueno M; Segovia Cubero J
    Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):908-9. PubMed ID: 26304135
    [No Abstract]   [Full Text] [Related]  

  • 49. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
    Winston DJ; Young JA; Pullarkat V; Papanicolaou GA; Vij R; Vance E; Alangaden GJ; Chemaly RF; Petersen F; Chao N; Klein J; Sprague K; Villano SA; Boeckh M
    Blood; 2008 Jun; 111(11):5403-10. PubMed ID: 18285548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
    Chou S; Hakki M; Villano S
    Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Qiu Y; Zhang Y; Teng M; Cheng S; Du Q; Yang L; Wang Q; Wang T; Wang Y; Dong Y; Dong H
    Transplantation; 2024 Apr; 108(4):1021-1032. PubMed ID: 38049935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation.
    Bassel M; Romanus D; Bo T; Sundberg AK; Okala S; Hirji I
    Antivir Ther; 2023 Oct; 28(5):13596535231195431. PubMed ID: 37657421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
    Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
    J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
    Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
    Chou S; Watters M; Sinha R; Kleiboeker S
    Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
    Chou S; Song K; Wu J; Bo T; Crumpacker C
    J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of the dynamics of human cytomegalovirus resistance to antiviral drugs by ultra-deep sequencing.
    Guermouche H; Burrel S; Mercier-Darty M; Kofman T; Rogier O; Pawlotsky JM; Boutolleau D; Rodriguez C
    Antiviral Res; 2020 Jan; 173():104647. PubMed ID: 31706899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resource Use and Financial Impact of Oral Step-Down Therapy for Resistant Cytomegalovirus in Solid Organ Transplant Recipients.
    Kleiboeker H; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA; Jorgenson MR
    Transplant Proc; 2024 Mar; 56(2):434-439. PubMed ID: 38355369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.
    Mehta Steinke SA; Alfares M; Valsamakis A; Shoham S; Arav-Boger R; Lees L; Ostrander D; Forman MS; Shedeck A; Ambinder RF; Jones RJ; Avery RK
    Transpl Infect Dis; 2021 Jun; 23(3):e13521. PubMed ID: 33220125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.